Biopharma company Jazz Pharmaceuticals (NASDAQ: JAZZ) will be reporting results this Monday after market hours. Here’s what to expect.
Jazz Pharmaceuticals beat analysts’ revenue expectations last quarter, reporting revenues of $1.21 billion, up 15.5% year on year. It was a very strong quarter for the company, with full-year revenue guidance exceeding analysts’ expectations.
Is Jazz Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Jazz Pharmaceuticals’s revenue to grow 7.4% year on year, in line with the 6.7% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Jazz Pharmaceuticals rarely misses Wall Street’s revenue estimates.
Looking at Jazz Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 38.6%, beating analysts’ expectations by 7.9%, and Supernus Pharmaceuticals reported revenues up 18.1%, topping estimates by 3.9%. Eli Lilly traded up 9.8% following the results while Supernus Pharmaceuticals’s stock price was unchanged.
Read our full analysis of Eli Lilly’s results here and Supernus Pharmaceuticals’s results here.
There has been positive sentiment among investors in the pharmaceuticals segment, with share prices up 5.6% on average over the last month. Jazz Pharmaceuticals is down 11.5% during the same time and is heading into earnings with an average analyst price target of $295.36 (compared to the current share price of $208.50).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
